Lyra Therapeutics, Inc.
LYRA
Rank in Stocks
#31526
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company,... Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Share Price
$0.19
Last synced: 2026-11-09
Market Cap
$2.95M
Change (1 day)
0.00%
Change (1 year)
-95.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lyra Therapeutics, Inc. (LYRA)
Category
Healthcare
Operating Margin for Lyra Therapeutics, Inc. (LYRA)
Operating Margin as of November 2026 TTM: -10,316.74%
According to Lyra Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -10,316.74%. At the end of 2025 the company had an operating margin of -7,794.47%.
Operating Margin history for Lyra Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -10,316.74% | 32.36% |
| 2025 | -7,794.47% | 24.10% |
| 2024 | -6,280.83% | 45.79% |
| 2023 | -4,308.09% | 4.29% |
| 2022 | -4,131.03% | -73.01% |
| 2021 | -15,303.51% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -583.52% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lyra Therapeutics, Inc.'s operating margin
What is Lyra Therapeutics, Inc.'s operating margin?
Lyra Therapeutics, Inc.'s operating margin is -10,316.74%, as of Nov 2026.
What was Lyra Therapeutics, Inc.'s operating margin in 2025?
In 2025, Lyra Therapeutics, Inc.'s operating margin was -7,794.47%, compared with -6,280.83% in 2024.
How has Lyra Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Lyra Therapeutics, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2021 (-15,303.51%).
How does Lyra Therapeutics, Inc.'s operating margin compare with similar companies?
Lyra Therapeutics, Inc.'s operating margin (-10,316.74%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.